Clinical Trials Logo

Clinical Trial Summary

L-carnitine is an amino acid that is naturally produced in the liver and kidneys, it is involved in transporting fatty acids across the mitochondrial membrane, it could be an important component in treating a fatty liver disease.

The investigators conduct a study to evaluate the efficacy of the combination of L-Carnitine and Magnesium as a treatment for fatty liver.


Clinical Trial Description

A phase 3, randomized, double blind placebo controlled study that evaluate the efficacy of L-Carnitine and Magnesium as a treatment for fatty liver, 60 eligible patients with a diagnosis of NAFDL will be randomly assigned in a 1:1 ratio to receive either the trial product " SLIM WATER" that contains L-CARNITINE and MAGNESIUM for a duration of 16 weeks, or placebo for the initial 8 weeks and continue another 8 weeks with the trial product "SLIM WATER". `Follow up time is estimated to be 24 week based on monthly clinic visits and accordingly assessment of lipid profile, weight and insulin resistance.

Fibrotest will be used at the beginning of the trial and at the end (week 16) comparing the fat content before and after the treatment. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03319199
Study type Interventional
Source HaEmek Medical Center, Israel
Contact
Status Completed
Phase N/A
Start date October 30, 2017
Completion date July 25, 2018

See also
  Status Clinical Trial Phase
Recruiting NCT05220956 - Impact of Time-restricted Feeding in NAFLD N/A
Active, not recruiting NCT04067440 - Characterization of the Microbiome in Peritoneum, Jejunum, Rectum and Stool
Completed NCT04509245 - The Effects of a Novel Lifestyle Intervention Program on Insulin Sensitivity in Type 2 Diabetes N/A
Completed NCT03656744 - A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM) Phase 2
Not yet recruiting NCT06117137 - The Impact Of SGLT2 -I on Metabolic Dysfunction -Associated Steatotic Liver Disease In Patients With Type 2 Diabetes Mellitus Phase 3
Completed NCT02132780 - Autonomic Dysfunction in Non-Alcoholic Fatty Liver Disease N/A
Active, not recruiting NCT04241575 - Identification of Fatty Liver With Advanced Fibrosis in Type 2 Diabetes Using Simple Fibrosis Scores and Electronic Reminder Messages N/A
Completed NCT02290106 - Effects of Pitavastatin on Insulin Sensitivity and Liver Fat N/A
Completed NCT03784716 - Ketogenic Diet in Non-alcoholic Fatty Liver Disease N/A
Recruiting NCT05558592 - Evaluation of the Effects of Orange Consumption on Carbohydrate and Lipid Metabolism in Subjects With MAFLD (Metabolic Associated Fatty Liver Disease) N/A
Recruiting NCT05855239 - Quantification of Hepatic Steatosis With Different Ultrasound Frequency
Recruiting NCT05877547 - A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013) Phase 2
Completed NCT04462562 - Quantitative US for Evaluation of Hepatic Steatosis in NAFLD N/A
Completed NCT04054297 - Glycemic Index/Saturated Fatty Acid Diet and Hepatic Fat N/A
Completed NCT03260543 - Efficacy and Safety of Fermented Ginseng Powder on Liver Function N/A
Not yet recruiting NCT06215131 - Feasibility of Immersive Virtual Reality Dietician Program in Metabolic-dysfunction Associated Steatotic Liver Disease N/A
Completed NCT03593343 - Hepatic Glycogen and Fat Oxidation N/A
Recruiting NCT06257732 - Different Exercise Modalities in the Treatment of NAFLD and Their Impact on Myokines N/A
Completed NCT02983669 - The Effects of Zataria Multiflora Boiss (Shirazi's Thyme) on Nonalcoholic Fatty Liver Disease N/A
Recruiting NCT02764047 - Probiotics in the Treatment of NAFLD N/A